Virongy focuses on creating cutting-edge technologies in virology, viral vector-based gene therapy, virus-host cell biology, and viral immunology. We develop new technologies that can be used for scientific discoveries, clinical diagnostics, and disease treatment. Virongy has discovered and developed key technologies and products including infectin, lentiviral vector, HIV reporter cell, etc.

Infectin

Learn More About Infectin

Infectin is designed to facilitate viral penetration of the cortical actin barrier, thereby greatly facilitating productive infection and the delivery of viral vectors into cells. Infectin can be used in the gene therapy field to facilitate the delivery of viral vectors. It can also facilitate the intracellular delivery of macromolecules such as therapeutic drugs, proteins, or nucleic acids. Virongy developed Infectin based on the scientific theory that the actin cytoskeleton is a natural barrier for viral entry and intracellular migration (Yoder et al., Cell, 2008, 134:782).

Ha-CoV-2 and Ha-CoV-2 Variants

Learn More About Ha-CoV-2

Ha-CoV-2 is a newly developed hybrid SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2020). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-psedoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirus-based vector for rapid (6 hours) and robust expression of reporter genes. Ha-CoV-2 represents a major technology advancement in the development of SARS-CoV-2 pseudoviruses, and serves as platforms for rapid and robust quantification of neutralizing antibodies, viral mutants, and antiviral drugs (Dabbagh et al., 2021; He et al., 2021).

HIV Rev-dependent Lentiviral Vector

Our HIV Rev-dependent lentiviral vector can selectively express therapeutic genes only in HIV-infected cells. This technology can be used to develop therapeutic vaccines or for therapeutic targeting of HIV reservoirs (Wang et al., 2010, Gene Ther. 17:1063).

HIV Rev-dependent Reporter Cells

Learn More About HIV Reporter Cells

These HIV Rev-dependent reporter cells are the best HIV-indicator cells on the market, with the highest specificity and accuracy in quantifying HIV infection. They can be used for anti-HIV drug screening, anti-HIV antibody screening, and the screening of anti-HIV compounds targeting host restriction or dependency factors (Wu et al., 2007, Curr HIV Res. 5:394).